Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Sarcoma 1

Conditions

Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Neoplasms 1Hemangiosarcoma 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1

Interventions

Specimen Handling 321Magnetic Resonance Spectroscopy 275pembrolizumab 267Carboplatin 190Cyclophosphamide 185Biopsy 178Cisplatin 164Gemcitabine 139Paclitaxel 137Bevacizumab 123fludarabine 122Nivolumab 117Radiotherapy 113Oxaliplatin 94venetoclax 92Docetaxel 90Fluorouracil 88Capecitabine 88Dexamethasone 85Drug Therapy 76Pemetrexed 75Rituximab 73durvalumab 71Leucovorin 71Blood Specimen Collection 70Radiosurgery 69Standard of Care 67atezolizumab 64Doxorubicin 64Radiation 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × 4-hydroxy-N-desmethyltamoxifen × 90 days × Clear all
NCT06075953 2026-05-22

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
400 enrolled
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡